Defense Health Program DoD Rare Cancers Research Program anticipated funding opportunities for FY20

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FY20 Defense Appropriations Act provides funding to the Department of Defense Rare Cancers Research Program to support for research of exceptional scientific merit in the area of rare cancers research. The RCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login